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The blood-brain barrier (BBB) poses an obstacle in the delivery of drugs to the brain. Bovine 
milk exosomes (BME) are explored for delivering antisense oligonucleotides to tumors, because 
BME are bioavailable and protect RNA cargos against degradation in the gastrointestinal tract. 
This study had the following objectives: 1) assess the transport kinetics of BME and their RNA 
cargos and secretion of RNA across the apical membrane in murine cerebral cortex endothelial 
bEnd.3 cells and 2) determine whether murine brain BV2 microglia have the potential to 
accumulate and, therefore, eliminate BME that crossed the BBB. The uptake of BME labeled 
with a lipophilic membrane dye followed Michaelis-Menten kinetics in bEnd.3 cells: Vmax = 0.77 
± 0.20 x 1011 BME/(10,000 cells x 45 min); Km = 1.8 ± 2.2 x 10
11 BME/mL. Transport kinetics 
were similar in BV2 microglia compared to bEnd.3 cells. When BME were labeled with an 
RNA-reactive dye and uptake was analyzed by using Z-stack confocal microscopy, it was 
apparent that BME entered the cytoplasm of bEnd.3 cells. Studies of BME transfected with 
fluorophore-labeled miR-34a suggested that detectable amounts of miR-34a were transported 
from the apical into the basolateral compartment in dual chamber systems. We conclude that 
BME deserve further exploration for drug delivery across the BBB.
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Extracellular vesicles 
The term extracellular vesicles (EVs) refers to the various types of membrane-bound vesicles 
secreted by virtually all cell types including prokaryotes and eukaryotes. As determined by 
their biogenesis, size, morphology and content, extracellular vesicles have been broadly 
classified into 3 sub-groups: exosomes, microvesicles and apoptotic bodies [1] and more 
recently classified into two classes: exosomes and microvesicles [2]. Although, previously 
considered as waste products from cells [3], EVs particularly exosomes, are now better 
understood to play critical roles in cell-to-cell communication. A number of mechanisms by 
which EVs are taken up by recipient cells have been proposed through studies using inhibitors 
of specific pathways, antibodies and knockdown experiments, these proposed mechanisms 
include fusion of EVs with plasma membrane of cells, clathrin and caveolin mediated 
endocytosis, phagocytosis and macropinocytosis (Figure 1.1) [4]. In addition, the specific 
proteins displayed by EVs provide information about their cell type of origin, fate and 
function [2]. 
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Figure 1.1 Proposed mechanisms of EV uptake by recipient cells. Adapted from Mulcahy et al., 
2014 [4]. 
Exosomes and RNAs 
Exosomes are nano-vesicles of 30 nm - 100 nm in size that are formed by the inward budding of 
the plasma membrane, which gives rise to the early endosome. The process of early and late 
endosome maturation leads to the formation of multivesicular bodies that fuse to the plasma 
membranes to release the enclosed intraluminal vesicles which are then called exosomes [5, 6] 
(Figure 1.2). Exosomes contain various cargos such as nucleic acids, lipids and proteins and can 
be considered the most biological significant class of EVs because of their critical role in 
protecting and transporting these labile cargos through endocytosis of exosomes into recipient 
cells [7, 8]. Also noteworthy is the knowledge that loading of RNA cargos into exosomes 
involves nonrandom sorting mechanisms [9]. These features make exosomes appealing vehicles 
for targeted delivery of drugs and biomolecules for which they are currently being extensively 
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studied [10-12]. Naturally occurring exosomes found in bovine milk show great potential as a 
scalable source for biomolecule delivery due to their size, biocompatibility, safety and cost-
effectiveness making them advantageous over synthetic nanoparticle formulations [12]. 
Mature microRNAs are short non-coding RNAs (approximately 22 nucleotides long) that 
regulate gene expression by pairing with 3’ untranslated regions (UTR) of target mRNAs. 
Perfect complementarity between the miRNA and target mRNA leads to mRNA degradation 
whereas partial complementarity leads to inhibition of translation [13-15]. The regulation of 
genes by miRNAs has been implicated in numerous physiological and pathological conditions in 
humans such as cancer, cardiovascular diseases, schizophrenia, diabetes and obesity [16-22]. 
MiRNAs in exosomes have been studied and reports suggest that manipulating exosomal 
miRNAs ex vivo may be an efficient tool to deliver miRNAs to target specific organs [10, 23].   
Our research group discovered that miRNA cargos present in bovine milk are bioavailable to 
humans and other non-bovine species and can regulate genes and metabolism in these species [7, 
8, 24]. Related studies also demonstrated that miRNA cargos in BME accumulate primarily in 
the intestinal mucosa, liver, spleen and brain when administered to mice [25], and that depletion of 
milk exosomes and RNA from mice diets affect sensorimotor gating and cognitive performance 
in mice such as spatial learning and memory [26]. Also, it was recently observed that a 
significant amount of microbial RNAs are present in BME and ongoing studies suggest that these 
are bioavailable in mice and humans and possess biological activity therein (Wu et al., 
unpublished). 
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Figure 1. 2 Exosome biogenesis and release from the plasma membrane of cells. (A) Intraluminal 
vesicles contained in MVEs fuse with the plasma membrane of the cell; (B) releasing its contents 
(now exosomes) to the neighboring cell. Adapted from Raposo et al., 2013 [27]. 
The Blood-Brain Barrier (BBB) 
The BBB is a highly selectively permeable barrier that line the blood vessels in the brain. It 
plays a critical role in the maintenance of homeostasis in the central nervous system by 
preventing the entry of potentially harmful compounds while allowing passage of required 
nutrients into the brain and efflux of waste products. The BBB also protects the brain from 
changes in ionic composition that occur during daily activities [28]. It is formed primarily by 
the brain endothelial cells that line the cerebral capillaries with support from astrocytes and 
pericytes in the brain (Figure 1.3). These endothelial cells possess unique properties that 
support their function including complex tight junctions formed by transmembrane proteins 
(e.g. occludin, claudins and junctional adhesion molecules) and adaptor proteins such as 
zonula occludens protein 1 (ZO-1).  [28, 29]. 
Astrocytes have also been shown to possess significant function in upregulating BBB features 
such as expression of tight junctions (physical barrier), polarized localization of transporters 
(transport barrier) and enzyme systems function (metabolic barrier) [28, 29]. Another important 
A B 
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cell type of the central nervous system (CNS) are the microglia. These cells are referred to as the 
resident macrophages of the CNS, playing a crucial role in the active immune system in the brain 
by eliminating cell debris, dead cells and other foreign compounds and particles thereby 
preventing infection and inflammation in the CNS. They also play a role in normal CNS 
development and maintenance. Of note, they are markedly different from macrophages of 
peripheral tissues due to their highly sensitive nature and ability to respond rapidly to very subtle 
changes in the brain microenvironment [30, 31]. In recent years however, microglia have been 
seen as mediators of neuroinflammation and their dysregulation has been implicated in 
neurodegenerative diseases and brain cancers [31, 32]. 
 
Figure 1. 3 Cellular components of the blood-brain barrier (BBB) are shown including closely 
associated cell types, transporters and receptors as well as inducing factors. EAAT1–3, 
excitatory amino acid transporters 1–3; GLUT1, glucose transporter 1; LAT1, L-system for large 
neutral amino acids; Pgp, P-glycoprotein. 5-HT, 5-hydroxytryptamine (serotonin); ANG1, 
angiopoetin 1; bFGF, basic fibroblast growth factor; ET1, endothelin 1; GDNF, glial cell line-
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derived neurotrophic factor; LIF, leukemia inhibitory factor; P2Y2, purinergic receptor; TGFβ, 
transforming growth factor-β; TIE2, endothelium-specific receptor tyrosine kinase 2. Adapted 
from Abbott et al., 2006 [28]. 
Methods of assessing transport across the BBB 
The BBB structure and function has been the focus of many studies because it prevents 
successful delivery of therapeutically relevant amounts of drugs to the brain, thereby blocking 
the development of neuropharmaceuticals for the treatment of brain related diseases [29, 33]. As 
a result, several methods have been developed to assess BBB function and the transport of 
molecules across the BBB in normal and pathological conditions. These include the use of in 
vivo approaches such as intravenous injections, brain perfusion methods, positron emission 
tomography, single-photon emission computed tomography and serial two-photon tomography, 
while in vitro studies include the use of two-dimensional (2-D) transwell systems and three-
dimensional (3-D) systems (extracellular matrix (ECM)-based models, spheroidal models and 
microfluidic models), details of which have been discussed in these articles [34-36].  
Transwell-systems are a widely used model of the BBB, in which monolayers of brain 
endothelial cells are cultured on apical side of membrane-coated inserts and astrocytes and/or 
pericytes are cultured underneath inserts or in the bottom of multi-well plates (Figure 1.4). 
Although, it lacks the intact in-vivo organization of components of the BBB, this system has 
been used for its time and cost effectiveness, ease of maintenance and is recommended for 
application in in vitro transport and permeability studies [35]. 
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Figure 1. 4 Schematic representation of a 2-D co-culture transwell system showing endothelial 
cells on apical inserts and astrocytes in the basolateral chamber.  
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ABSTRACT 
The blood-brain barrier (BBB) poses an obstacle in the delivery of drugs to the brain. Bovine 
milk exosomes (BME) are explored for delivering antisense oligonucleotides to tumors, because 
BME are bioavailable and protect RNA cargos against degradation in the gastrointestinal tract. 
This study had the following objectives: 1) assess the transport kinetics of BME and their RNA 
cargos and secretion of RNA across the apical membrane in murine cerebral cortex endothelial 
bEnd.3 cells and 2) determine whether murine brain BV2 microglia have the potential to 
accumulate and, therefore, eliminate BME that crossed the BBB. The uptake of BME labeled 
with a lipophilic membrane dye followed Michaelis-Menten kinetics in bEnd.3 cells: Vmax = 0.77 
± 0.20 x 1011 BME/(10,000 cells x 45 min); Km = 1.8 ± 2.2 x 10
11 BME/mL. Transport kinetics 
were similar in BV2 microglia compared to bEnd.3 cells. When BME were labeled with an 
RNA-reactive dye and uptake was analyzed by using Z-stack confocal microscopy, it was 
apparent that BME entered the cytoplasm of bEnd.3 cells. Studies of BME transfected with 
fluorophore-labeled miR-34a suggested that detectable amounts of miR-34a were transported 
from the apical into the basolateral compartment in dual chamber systems. We conclude that 
BME deserve further exploration for drug delivery across the BBB. 
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INTRODUCTION 
Most cells secrete exosomes (30 - 120 nm diameter), which transfer regulatory cargos such as 
lipids, proteins and various species of RNA from donor cells to adjacent or distant recipient cells 
1, 2. Exosomes may trigger responses in recipient cells through binding to surface receptors or by 
delivering regulatory cargos to the cell interior 1-3. Once inside cells, exosomes and their cargos 
may be degraded in lysosomes or elicit responses such as microRNA-dependent changes in gene 
expression 1, 2. Among exosome cargos, microRNAs are of particular interest because they 
regulate more than 60% of human genes and loss of microRNA maturation is embryonic lethal 4, 
5.  
Exosomes and their microRNA and protein cargos are not solely obtained from endogenous 
synthesis but may also be absorbed from food matrices such as bovine milk 6-8. Encapsulation of 
RNA in bovine milk exosomes (BME) confers protection against degradation under harsh 
conditions present in the gastrointestinal tract (low pH, RNases) and a pathway to intestinal 
absorption by endocytosis 7, 9. Primary accumulation sites of BME and their microRNA cargos 
include intestinal mucosa, liver, spleen and brain 8. Evidence suggests that resident macrophages 
accumulate foreign exosomes and thereby contribute to the observed distribution patterns, e.g., 
Kupffer cells in the liver and microglia in brain 10, 11. 
Our discovery that BME and their cargos are bioavailable have sparked an interest in using 
BME as a scalable vehicle for the delivery of drugs 12, 13. BME do not elicit adverse immune 
reactions following oral administration to humans, rats and human peripheral blood mononuclear 
cells ex vivo (12, E. Mutai et al. in press). Engineered exosomes have been used to deliver 
antisense oligonucleotides (small interfering RNA) to pancreas and inhibition of the expression 
of a pro-carcinogenic mutant of KRAS 14. The delivery of drugs to the brain poses a unique 
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challenge because of the blood-brain barrier (BBB), which prevents many compounds, including 
drugs from entering the brain 15. It is unknown whether the accumulation of BME and 
microRNAs reported in previous studies represent compounds in blood vessels or whether BME 
and cargos crossed the BBB and entered brain tissue, although evidence suggests that the latter is 
the case (8, see Discussion). 
The objectives of this study were to: 1) assess the transport kinetics of BME and their RNA 
cargos in murine cerebral cortex endothelial bEnd.3 cells, and secretion of RNA into the 
basolateral chamber in a co-culture model of the BBB, and 2) determine whether murine brain 
BV2 microglia have the potential to accumulate and, therefore, eliminate BME that crossed the 
BBB. 
 
EXPERIMENTAL SECTION 
Cell culture 
Murine brain endothelial bEnd.3 cells and murine C8-D1A astrocytes were purchased from 
American Type Culture Collection. Murine BV2 microglia were obtained from Dr. Sanjay 
Maggirwar (University of Rochester Medical Center, Rochester, NY). All cells were cultured in 
Dulbecco’s Minimal Essential Media (Hyclone) containing 10% fetal bovine serum (Atlanta 
Biologicals), 1% penicillin (100 IU/mL) and streptomycin (100 μg/mL) (Gibco), and 0.1% 
sodium pyruvate (Sigma) and were maintained in a humidified atmosphere at  37 ˚C and 5% 
CO2. bEnd.3 cells and BV2 microglia were used from passages 24 – 30 and 15 – 25 respectively. 
ATCC did not provide information about passage number for C8-D1A cells; we passaged them 
up to 15 times in our laboratory.  
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Exosome isolation and authentication 
Fat-free bovine milk was obtained from a local grocery store and exosomes were isolated from 
milk by ultracentrifugation (Sorvall WX Ultra 80, F37L-8 x 100 rotor; Thermo Scientific) as 
described previously, with minor modifications 7, 16. Characterization was done using scanning 
electron microscopy (Hitachi S4700, Hitachi) and nanoparticle tracking analysis (NanoSight 
NS300; Malvern). Exosomes were suspended in sterile phosphate-buffered saline (PBS) and 
stored at -80 °C until use. 
 
Transport studies in bEnd.3 cells and BV2 microglia 
For transport studies, bEnd.3 cells and BV2 microglia were seeded in conditioned media, 
prepared by using exosome-depleted fetal bovine serum (120,000 g, 18 h). Seeding densities 
were 7.5 x 103 bEnd.3 cells and 1 x 104 BV2 microglia per well in 96-well polystyrene plates. 
Cells were allowed to reach 70 – 80% confluence prior to conducting transport studies.  
BME were labeled with the lipophilic FM 4-64 membrane dye (excitation 515 nm, emission 
640 nm, Molecular Probes). Eight microliters of stock solution of FM 4-64 (5.9 mmol/L) was 
added to 1 mL of exosome suspension and incubated at 37 ºC for 30 min, followed by 
ultracentrifugation at 120,000 g at 4 ºC for 90 min to remove excess dye. In time-course 
experiments, bEnd.3 cells and BV2 microglia were incubated with 6 x 1011 BME/mL at 37 °C 
and 5% CO2 for up to 6 h. In dose-response experiments, bEnd.3 cells and BV2 microglia were 
incubated with 3 x 1011 to 15 x 1011 BME/mL at 37 °C and 5% CO2 for 45 min. After incubation, 
the media supernatant was removed, and cells were washed twice with pre-warmed PBS. 
Controls were prepared by incubating cells with medium only, and by removing BME 
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immediately after addition to cultures (t = 0 h). BME uptake by cells was measured using a 
microplate fluorescence reader (BioTek Instruments).  
 
Z-stack confocal microscopy 
Z-stack confocal microscopy was used to confirm that BME entered the cell interior, and that the 
uptake of FM 4-64-labeled BME was not an artifact caused by the transfer of FM 4-64 to 
lipophilic compounds other than BME membranes 17. Briefly, mRNA cargos in BME were 
labeled by using the ExoGlow-RNATM EV Labeling Kit (excitation 485 nm, emission 537 nm, 
System Biosciences) following the manufacturer’s recommendations. bEnd.3 cells and BV2 
microglia were seeded at a density of 3 x 104 and 4 x 104 cells per well (600µL medium), 
respectively, in 24-well polystyrene plates. After 24 h in culture, media were replenished and 50 
µL of ExoGlow-RNATM-labeled BME (stock, 5 x 1011 BME/mL) was added to each well and 
cells were incubated at 37 °C and 5% CO2 for 24 h. Prior to imaging, media supernatant was 
removed and cells were washed twice with pre-warmed PBS, fixed with 4% paraformaldehyde 
(PFA) at room temperature (RT) for 15 min (Electron Microscopy Sciences) and permeabilized 
with 0.1% Triton X-100 (J.T. Baker; RT, 30 min) 18. Actin filaments and nuclei were stained 
with Alexa Fluor 568 phalloidin (excitation 578 nm, emission 600 nm, Invitrogen) and DAPI 
(excitation 358 nm, emission 461 nm, Invitrogen), respectively (RT, 30 min). Images were 
obtained using an A1R-Ti2 confocal system (Nikon). 
 
Blood-brain barrier model 
The transport of BME across the BBB was assessed by using co-cultures of bEnd.3 cells and C8-
D1A astrocytes. We chose this co-culture model, because astrocytes improve the barrier 
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properties of brain endothelial cell cultures (19, see Results). Studies were conducted using a 
transwell, dual chamber system (0.4 μm pore size, 6.5 mm diameter, 24-well polystyrene plates, 
Costar) 7. Astrocytes were seeded in the basolateral chamber of 24-well polystyrene plates at a 
density of 4 × 104 cells/well and cultured for two days to allow for adherence to plastic surfaces. 
bEnd.3 cells were seeded in the polyester transwell inserts at a density of 6.6 × 104 cells/insert. 
Cell cultures were maintained in a humidified atmosphere at 37 ˚C and 5% CO2 and the 
basolateral medium was renewed daily. Cells were cultured in complete Dulbecco’s Minimal 
Essential Medium supplemented with 10% fetal bovine serum, 1% penicillin (100 IU/mL), 
streptomycin (100 μg/mL) and 0.1% sodium pyruvate.  
bEnd.3 cell monolayer integrity was assessed by measuring transepithelial electrical resistance 
(TEER) on a daily basis 19. TEER was measured by using an Epithelial Voltohmmeter (EVOM) 
with STX2 electrodes (EMD Millipore). Resistance readings of cell-free inserts were subtracted 
from resistance readings of cell-containing inserts. Values are expressed as Ohm x cm2(Ω cm2). 
Lucifer yellow (LY) permeability assay was carried out as previously described 20. Permeability 
coefficients (Pc) were calculated as follows and are expressed in units of cm/s for both BME 
transport and LY permeability for bEnd.3 cell monolayers: 
Pc [cm/s] =  
Vr x Cf
Ci x A x t
 
where Pc is the permeability coefficient; Vr is the receiver volume in mL; Cf is the final  
receiver concentration in the basolateral chamber in units of BME/100 µL and µM for BME and 
LY, respectively; Ci is the initial apical concentration in the apical chamber in units of BME/100 
µL and µM for BME and LY, respectively; and A is the membrane growth area in cm2 and t is 
the assay time in seconds.  
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Monolayer integrity was also evaluated by assessing the expression of zonula occludens-1 
(ZO-1) protein 21 in post-confluent bEnd.3 cells on coverslips (VWR). Cells were fixed and 
permeabilized as previously described 18, blocked with LI-COR blocking buffer (LI-COR; RT, 1 
h) and incubated with Alexa Fluor 488-conjugated anti-ZO-1 (excitation 490 nm, emission 525 
nm, Santa Cruz Biotechnology) at RT for 1 h. Slides were counterstained by using DAPI (RT, 15 
min) and images were obtained by using an A1R-Ti2 confocal microscope.  
Studies of BME transport across the bEnd.3 monolayer were initiated by removing 
Dulbecco’s Minimal Essential Medium from both inserts and basolateral chambers and washing 
inserts and basolateral chambers three times with pre-warmed Hank’s balanced salt solution 
(HBSS, Gibco). Next, 100 µL HBSS containing 6 x 1011 to 24 x 1011 fluorophore-labeled 
BME/100 µL was added to the inserts. Fluorophore labeling was achieved by transfecting 1012 
BME with 150 pmoles of 5’-IRDye-labeled miR-34a, to produce a final stock concentration of 2 
x 1013 transfected BME8. Cells were kept at 37 ˚C and 5% CO2. At timed intervals (15, 30, 45, 
60 min), 100 µL of sample was collected from the basolateral chambers and transferred into a 
96-well polystyrene plate for fluorescence analysis using an Odyssey imaging system (LI-COR). 
The buffer in the lower chamber was replenished with an equal volume of HBSS each time a 
sample was collected. Fluorescence readings of sample in HBSS collected at different time 
points were subtracted from HBSS only. 
 
Statistical analyses  
Homogeneity of variances was assessed by using the Brown-Forsythe test 22. The variance of 
data was heterogeneous for BBB transport in dose-dependent transwell studies even after log 
transformation; the data were analyzed by using the Kruskal – Wallis test followed by Dunn’s 
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multiple comparison test. Data from time-dependent transwell studies were analyzed by using 
repeated measures one-way ANOVA followed by Tukey’s multiple comparisons test. 
Comparisons between two groups were analyzed by using the unpaired two-tailed t-test. Data 
analysis was conducted by using GraphPad Prism 6.0 (GraphPad Software). Data are reported as 
mean ± SEM. Differences were considered signiﬁcant if P < 0.05.    
 
RESULTS 
Transport of bovine milk exosome in bEnd.3 cells and BV2 microglia 
The uptake of FM 4-64-labeled BME increased linearly with time in bEnd.3 cells (y = 3.1 x 108x 
+ 5.6 x 109; R2 = 0.99) and BV2 microglia (y = 3.3 x 108x + 2.5 x 1010; R2 = 0.86) for the entire 
observation period (Figure 2.1 A,B). Subsequent transport studies were conducted for 45 
minutes. The uptake of FM 4-64 labeled BME by bEnd.3 and BV2 cells exhibited saturation 
kinetics and was modeled using the Michaelis-Menten equation (Figure 2.1 C). In bEnd.3 cells, 
maximal transport rate (Vmax) and Michaelis-Menten constant (Km) were 0.77 ± 0.18 x 10
11 
BME/(10,000 cells x 45 min) and 1.8 ± 2.0 x 1011 BME/mL respectively, whereas in BV2 
microglia Vmax and Km were 0.66 ± 0.14 x 10
11 BME/(10,000 cells x 45 min) and 1.9 ± 1.9 x 
1011 BME/mL respectively. Analysis by Z-stack confocal microscopy suggested that BME 
entered the interior as opposed to adhering to the surface in bEnd.3 cells (Figure 2.2 and Figure 
S.3) and BV2 microglia (Figure S.5). When maximal intensity projections of all focal planes for 
each channel were obtained, extranuclear localization of BME was apparent in bEnd.3 cells and 
BV2 microglia (Figure 2.3 A,B); no exosome signal was detected in BME-free controls. 
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Transport of miR-34a across the blood-brain barrier 
MiR-34a transfected into BME was transported across the BBB in a bEnd.3 cell dual chamber 
system. When 6.0 x 1011 BME, transfected with miR-34a were added to the apical side of bEnd.3 
cells in transwell inserts, the transfer of miR-34a across cell monolayers into the basolateral 
chamber increased with time. The transport of mass was modest: 53 ± 4.2 arbitrary units of 
fluorescence at baseline (background) vs 83 ± 5.9 arbitrary units of fluorescence at t = 60 min (P 
< 0.05; Figure 2.4A). Pc values suggested that the permeability of monolayers was similar for 
each time point measured in the study (P > 0.05; Figure 2.4B). When increasing numbers of 
BME were added to the apical chamber, the Pc values of miR-34a transport across the BBB 
decreased, suggesting a saturable transport across the endothelial monolayer (Figure 2.4C).  
bEnd.3 cell monolayers on inserts were characterized using daily TEER measurements, LY 
permeability measurements and ZO-1 tight junction expression. Daily TEER measurements 
showed a steady increase until days 4 - 5 post seeding when readings reached a plateau (Figure 
2.5A). Endothelial cell monoculture showed significantly lower TEER values (~24 Ω x cm2) 
compared to endothelial cell/astrocyte co-cultures (~34 Ω x cm2); in monocultures TEER values 
peaked on day 3. Subsequent permeability studies were carried out in co-cultures and data were 
measured on day 5. These data are consistent with previous reports suggesting that the presence 
of astrocytes enhances the formation of tight bEnd.3 cell monolayers19. bEnd.3 monolayers using 
antibody to ZO-1 protein revealed tight junctions expressed ZO-1, which is a marker for the 
formation of tight junctions 23 (Figure 2.5B). Pc values were ~ 6.7 x 10
- 6 cm/s in LY 
permeability assays, which is similar to previous studies of BBB in endothelial cells from rat and 
bovine origin21. 
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DISCUSSION 
This paper is first to show that brain endothelial cells take up BME administered. In a previous 
paper we reported that milk exosomes and select protein and microRNA cargos accumulate in 
the brain in pigs and mice, but we did not assess whether the exosomes were in the blood vessels 
or delivered to brain cells8. This paper advanced the existing knowledge base by demonstrating 
that BME enter the cytoplasm in murine brain endothelial cells and are subsequently transferred 
across the basolateral membrane, which are the two key events in the transport of compounds 
across the BBB23. Our observation that BME cross the BBB barrier is consistent with a previous 
study, which suggested that exosomes from the human glioblastoma cell line, LN18 delivered 
cre recombinase to the brain in Ai14 reporter mice, eliciting a switch from the expression of 
green fluorescent protein to the expression of tdTomato in cerebellum, cortex, hippocampus, 
olfactory bulb and striatum24. The study also suggest that exosomes transfer cargos in quantities 
sufficient to elicit biological effects, in that case cre recombination. While the transfer of miR-
34a cargo across a bEnd.3 cell monolayer was quantitatively moderate (approximately two times 
background), the depletion of BME was sufficient to elicit a significant loss in spatial learning 
and memory in preliminary studies in mice fed BME and RNA-depleted diets25. Note that small 
changes in microRNA abundance may alter gene expression, with the effect size depending on 
the pool of mRNA transcripts targets in a given cell or tissue 26. Also, distinct microRNA cargos 
in BME have unique distribution patterns and it is conceivable that microRNAs other than miR-
34a accumulate in comparably large quantities in brain8. The distribution of BME in bEnd.3 cells 
and BV2 microglia reported in this paper is consistent with expectations: BME accumulated in 
the extranuclear space, presumably in endosomes, multivesicular bodies and lysosomes1, 2.  
10 
 
 
One of the strengths of this study is that the data reported here are not fraught with the 
uncertainty whether a (lipophilic) dye dissociated from the BME membrane and whether BME 
entered cells as opposed to adhere to the cell surface. Lipophilic dyes such as DiR and PKH67 
may detach from membranes and transfer to lipoproteins and proteins, thereby causing artifacts 
in studies of exosome transport, bioavailability and distribution17. We formally excluded these 
possibilities by transfecting BME with miR-34a covalently conjugated with a fluorophore, and 
by confirming uptake into the cell interior by Z-stack confocal microscopy. In previous studies, 
we used fluorophore-quencher co-labeling to confirm that microRNA-fluorophore conjugates are 
stable when administered to mice8. Therefore, signals observed in BME are unlikely due to 
artifacts caused by the transfer of dye to lipophilic compounds other than BME membranes. This 
being said, the mere binding of exosomes to cell surfaces may also elicit cellular responses such 
as activation of p38 and pERK signaling3. 
Our studies suggest that the capacity and affinity for BME transport are similar in brain 
endothelial cells and macrophages (microglia). This is an important observation, because 
previous studies suggest that foreign exosomes are rapidly eliminated by macrophages11. Rapid 
elimination of BME by macrophages could reduce the biological activity of BME in both 
nutrition and drug delivery. Studies of bEnd.3 and BV2 cultures do not formally exclude the 
possibility that BME might be eliminated by macrophages in tissues other than brain in a whole 
organism. Future studies will need to determine whether BME transport across the BBB barrier 
is a selective process that discriminates against some sub-populations of BME. 
In conclusion, this study demonstrated that BME are taken up by the brain which is 
consistent with effects reported for dietary BME and brain function, and the use of BME for 
delivering antisense-based cancer drugs across the BBB. Future studies will need to identify 
11 
 
 
factors that permit directing BME to target sites, e.g., tumors and determine whether the uptake 
of BME by cancerous cells exceeds that of non-cancerous cells. 
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Figure 2. 1 The uptake of bovine milk exosomes (BME) by brain endothelial bEnd.3 cells and 
BV2 microglia increases linearly with time and is a saturable process. Time courses of BME 
A 
C 
B 
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uptake by bEnd.3 cells (A) and BV2 microglia (B) for a concentration of 6 x 1011 BME/mL 
media (n = 3 biological repeats). Dose-response curves of BME uptake by bEnd.3 cells and BV2 
microglia for an incubation time of 45 min, n = 3 biological repeats (C). Data are presented as 
mean ± SEM.   
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Figure 2. 2 BME enter the interior of bEnd.3 cells. Images represent select focal planes acquired 
by Z-stack confocal microscopy; see Figure S.3 for a complete set of planes that were acquired. 
mRNA in BME was labeled with ExoGlow-RNATM (green). Nuclei and actin (cytoplasm) were 
stained with DAPI (blue) and Alexa Fluor 568 phalloidin (red), respectively. Merged images are 
shown. Magnification = 60x.  
50 µm 50 µm 50 µm 
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Figure 2. 3 BME localize to the extranuclear space in endothelial bEnd.3 cells and BV2 
microglia. Cells were incubated for 24 h with BME in which mRNA was labeled with ExoGlow-
RNATM (green); controls were cells only. Nuclei and actin (cytoplasm) were stained with DAPI 
(blue) and Alexa Fluor 568 phalloidin (red) respectively and assessed by Z-stack confocal 
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microscopy (see Figures S.3 – S.6) in bEnd.3 cells (A) and BV2 cells (B). Magnification = 60x.     
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Figure 2. 4 MiR-34a-loaded BME are transported across bEnd.3 cell monolayers. (A) Transport 
of miR-34a transfected exosomes across an in vitro BBB model increased with time. (B) 
Monolayers also showed similar permeability to BME at different time points, when bEnd.3 cell 
monolayers were administered 6.0 x 1011 BME transfected with miR-34a (n = 3 biological 
repeats). (C) When cells were administered increasing concentrations of BME: 6, 12 or 24 x 
1011, a decrease in permeability coefficient values was observed when measured at t = 1 h (n = 3 
biological repeats measured twice each). Data are presented as mean ± SEM. 
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Figure 2. 5 bEnd.3 cell cultures formed a tight monolayer. (A) Comparison of electrical 
resistance (TEER) in bEnd.3 cell monocultures and bEnd.3 cells co-cultured with astrocytes. 
TEER values reached a plateau at t = 4-5 days post seeding in bEnd.3 cells co-cultures (n = 3 
biological repeats, means ± SEM). *Significantly different compared to bEnd.3 cell 
monocultures (P < 0.05). (B) Immunostaining of ZO-1 in endothelial bEnd.3 monolayers. Cells 
were stained with anti-ZO1-conjugated Alexa Fluor 488 (green) and counterstained with DAPI 
(blue). Magnification = 60x; scale bar = 50 µm. 
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Figure S. 1 BME authentication was conducted using nanoparticle tracking analysis (A) and 
transmission electron microscopy (B).   
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Figure S. 2 Effect of BME on cell viability. bEnd.3 cells (A) and BV2 microglia (B) were 
administered FM 4-64 labeled BME at concentrations similar to those used in FM 4-64 transport 
assays (1.5 x 1011 – 24 x 1011 BME/mL) and monitored for 45 min. Viability was assessed using 
the thiazolyl blue tetrazolium bromide reagent. Data are presented as mean ± SEM (n = 3). 
Statistical signiﬁcance was assessed by one-way ANOVA. *, P < 0.05 when data were compared 
with BME-free control cells.  
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Figure S. 3 Overlay of individual Z-stack slices for bEnd.3 cells treatment group. Cells were 
incubated with BME in which mRNA was labeled with ExoGlow-RNATM (green) for 24 h. 
Nuclei and actin (cytoplasm) were stained with DAPI (blue) and Alexa Fluor 568 phalloidin 
(red) respectively. Magnification = 60x; scale bar = 50µm.   
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Figure S. 4 Overlay of individual Z-stack slices for bEnd.3 cells control group (cells only). 
Nuclei and actin (cytoplasm) were stained with DAPI (blue) and Alexa Fluor 568 phalloidin 
(red) respectively. Magnification = 60x; scale bar = 50µm.   
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Figure S. 5 Overlay of individual Z-stack slices for BV2 cells treatment group. Cells were 
incubated with BME in which mRNA was labeled with ExoGlow-RNATM (green) for 24 h. 
Nuclei and actin (cytoplasm) were stained with DAPI (blue) and Alexa Fluor 568 phalloidin 
(red) respectively. Magnification = 60x; scale bar = 50µm.   
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Figure S. 6 Overlay of individual Z-stack slices for BV2 cells control group (cells only). Nuclei 
and actin (cytoplasm) were stained with DAPI (blue) and Alexa Fluor 568 phalloidin (red) 
respectively. Magnification = 60x; scale bar = 50µm.   
  
50 µm 
50 µm 
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FUTURE STUDIES 
Till date, findings from our research group and others have shown that BME hold much promise 
as therapeutic drug delivery or biomolecule delivery vehicles due to their size, biocompatibility, 
safety and cost-effectiveness making them advantageous over synthetic nanoparticle 
formulations [1-4]. However, further research will be required to advance their therapeutic 
potential.  
In this study, we have shown the ability of brain endothelial cells to take up BME and RNA 
cargos and their transport across the BBB, which supports findings by Manca and colleagues on 
accumulation of exosome cargos in the brain [3]. To further these results, ongoing studies are 
looking into the biodistribution patterns of exosome cargos in the brain. In line with this report 
[3] which revealed the accumulation of miR-34a transfected exosomes and endogenous 
CD63/eGFP-labeled exosomes in the brain of wild-type mouse pups nursed by CD63/eGFP-
positive dams, ongoing experiments will examine what brain regions and cell types such as 
neurons or microglia may accumulate these exosomes. Knowledge of the localization of these 
exosomes could provide more insight into optimal delivery conditions in order to ensure 
maximum efficacy of therapeutically-delivered exosomes to the brain.  
Also, some studies in our lab have shown that glycoproteins on the surface of exosomes are 
important in exosome recognition by the recipient cell and their modiﬁcations were particularly 
important for the uptake of bovine milk exosomes by Caco-2 and FHs cells [5]. With relation to 
the brain, it will be interesting to see how these glycoprotein modifications may influence the 
targeting and delivery of BME and RNA cargos to different tissues particularly the brain, this 
area is being explored in ongoing studies in our lab. 
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In addition, research in our lab discovered that exosome and RNA supplementation or depletion 
from the diet of mice produces effects on the spatial learning and memory in mice [6]. This is an 
interesting finding and an understanding of the mechanisms behind it will be beneficial. Previous 
reports have linked spatial and recognition memory with the hippocampal region of the brain [7]. 
As such, current and future experiments are looking into examining if any observed difference 
may exist between hippocampal neurons in mice fed exosome sufficient and exosome depleted 
diet, which may, to some extent, explain the observed differences in spatial learning and 
memory. Information from these studies will contribute significantly to the application of BME 
as a potential therapeutic delivery system and the importance of BME in brain function.  
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Table 1. Dose - response data for bEnd.3 transport study with FM 4-64 labeled BME. 
Concentration 
(BME/mL) 
Uptake fluorescence (10,000 cells x 45 min) Mean SEM 
0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 
3.0E+11 2.8E+10 2.1E+10 0.0E+00 6.1E+10 8.7E+10 1.1E+10 1.0E+11 4.2E+09 6.1E+10 4.2E+10 1.3E+10 
6.0E+11 7.2E+10 7.2E+10 1.1E+11 1.4E+11 7.4E+10 3.2E+10 1.4E+11 0.0E+00 0.0E+00 7.0E+10 1.8E+10 
1.2E+12 1.0E+11 7.3E+10 5.8E+10 6.7E+10 4.5E+10 4.2E+10 1.4E+11 3.9E+10 0.0E+00 6.3E+10 1.3E+10 
1.5E+12 9.2E+10 4.3E+10 7.6E+09 7.1E+10 6.4E+10 6.7E+10 1.6E+11 2.7E+10 7.1E+10 6.7E+10 1.4E+10 
 
Table 2. Dose - response data for BV2 transport study with FM 4-64 labeled BME. 
Concentration 
(BME/mL) 
Uptake fluorescence (10,000 cells x 45 min) Mean SEM 
0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 
3.0E+11 8.0E+10 0.0E+00 0.0E+00 6.6E+10 0.0E+00 2.6E+10 5.0E+10 1.0E+11 5.0E+10 4.2E+10 1.3E+10 
6.0E+11 1.0E+11 0.0E+00 2.4E+10 1.3E+11 4.8E+09 3.9E+10 6.4E+10 5.5E+10 1.1E+10 4.8E+10 1.5E+10 
1.2E+12 1.1E+11 7.5E+09 3.5E+10 7.4E+10 4.1E+10 2.9E+10 1.0E+11 9.6E+10 8.0E+10 6.3E+10 1.2E+10 
1.5E+12 8.9E+10 4.3E+10 3.2E+10 5.8E+10 3.4E+10 6.1E+10 7.2E+10 5.2E+10 5.5E+10 5.5E+10 6.0E+09 
 
 Table 3. Time course data for bEnd.3 transport study with FM 4-64 labeled BME. 
Minutes Uptake fluorescence (10,000 cells) Mean SEM 
0 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 
15 8.0E+09 8.0E+10 0.0E+00 1.3E+09 2.1E+10 0.0E+00 0.0E+00 2.1E+10 0.0E+00 1.5E+10 8.7E+09 
30 1.0E+10 1.0E+11 4.0E+09 1.5E+10 2.1E+10 2.3E+10 0.0E+00 0.0E+00 0.0E+00 1.9E+10 1.0E+10 
60 4.0E+09 1.0E+11 5.0E+10 2.1E+10 2.1E+10 1.5E+10 0.0E+00 4.1E+10 0.0E+00 2.8E+10 1.1E+10 
90 4.0E+09 9.4E+10 8.0E+09 2.1E+10 1.1E+10 3.7E+10 0.0E+00 9.0E+10 2.1E+10 3.2E+10 1.2E+10 
120 1.0E+10 1.1E+11 4.0E+09 3.7E+10 3.7E+10 1.1E+10 0.0E+00 1.3E+11 2.8E+10 4.1E+10 1.6E+10 
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Table 4. Time course data for BV2 transport study with FM 4-64 labeled BME. 
Minutes Uptake fluorescence (10,000 cells) Mean SEM 
0 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 
15 3.5E+10 5.0E+10 4.0E+10 0.0E+00 5.3E+10 0.0E+00 0.0E+00 1.1E+11 0.0E+00 3.2E+10 1.2E+10 
30 6.4E+10 1.1E+11 5.0E+10 4.3E+10 1.7E+11 1.9E+10 0.0E+00 1.4E+11 0.0E+00 6.6E+10 2.0E+10 
60 0.0E+00 5.5E+10 2.6E+10 4.8E+10 8.2E+10 4.8E+09 0.0E+00 1.5E+11 0.0E+00 4.0E+10 1.7E+10 
90 6.0E+10 1.1E+11 0.0E+00 0.0E+00 3.9E+10 2.4E+10 2.9E+09 1.6E+11 0.0E+00 4.4E+10 1.9E+10 
120 7.4E+10 1.3E+11 1.1E+11 5.8E+10 1.2E+11 3.9E+10 2.9E+10 1.5E+11 0.0E+00 7.9E+10 1.7E+10 
240 2.0E+11 1.8E+11 1.5E+11 6.3E+10 6.8E+10 5.3E+10 2.9E+10 1.7E+11 1.2E+10 1.0E+11 2.4E+10 
360 1.5E+11 1.6E+11 1.4E+11 1.3E+11 1.2E+11 2.0E+11 1.0E+11 8.8E+10 2.1E+11 1.4E+11 1.4E+10 
 
 Table 5. TEER values for co-culture experiments. 
Days TEER (Ohm x cm2) Mean SEM 
1 11.5 11.0 14.2 13.9 12.0 13.4 15.7 12.8 14.1 13.2 0.5 
2 20.4 24.5 20.5 19.7 18.6 20.0 21.4 20.7 22.7 21.0 0.6 
3 25.0 25.8 30.9 31.2 28.5 29.7 29.3 30.3 29.5 28.9 0.7 
4 32.7 28.5 36.2 35.9 34.4 34.9 34.5 31.4 32.7 33.5 0.8 
5 34.1 37.0 35.1 36.4 34.9 36.4 31.2 31.7 31.8 34.3 0.7 
 
Table 6. TEER values for mono-culture experiments. 
Days TEER (Ohm x cm2) Mean SEM 
1 10.5 10.5 15.5 15.3 11.9 13.4 12.1 12.8 
 
0.8 
 
2 23.8 23.3 21.0 22.0 18.3 21.2 19.4 21.3 
 
0.8 
 
3 21.7 25.8 28.1 26.2 23.9 25.0 21.7 24.6 
 
0.9 
 
4 17.0 21.5 22.0 24.5 19.4 20.7 17.5 20.4 
 
1.0 
 
5 16.9 22.4 18.9 19.6 15.7 17.8 13.7 17.8 1.1 
240 2.8E+10 1.1E+11 2.2E+10 3.7E+10 5.1E+10 4.9E+10 1.2E+11 1.4E+11 1.2E+11 7.5E+10 1.5E+10 
360 8.0E+10 9.0E+10 1.5E+11 1.2E+11 1.2E+11 1.1E+11 4.1E+10 1.7E+11 2.4E+11 1.2E+11 1.9E+10 
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Table 7. Dose-dependent relationship for miR-34a transfected BME in transwell studies. 
Concentration 
(BME/mL) 
6 x 1011 1.2 x 1012 2.4 x 1012 
 
 
Permeability 
coefficient 
3.0E-06 2.8E-06 1.1E-06 
3.7E-06 2.5E-06 1.3E-06 
5.3E-06 2.3E-06 1.3E-06 
7.1E-06 2.4E-06 8.8E-07 
7.2E-06 2.5E-06 9.5E-07 
4.9E-06 2.3E-06 9.1E-07 
Mean 5.2E-06 2.5E-06 1.1E-06 
SEM 7.0E-07 8.2E-08 7.5E-08 
 
Table 8. Time-dependent relationship for miR-34a transfected BME in transwell studies. 
Minutes 15.0 30.0 45.0 60.0 
miRNA 
fluorescence 
15.7 15.6 14.7 22.1 
10.1 7.5 17.1 26.0 
10.9 28.3 30.2 37.8 
7.5 23.0 22.7 26.6 
44.5 40.5 54.3 44.6 
9.7 25.7 36.9 38.2 
14.0 16.3 12.8 31.0 
16.3 15.4 10.7 21.7 
14.5 10.6 8.8 18.1 
Mean 15.7 15.6 14.7 22.1 
SEM 10.1 7.5 17.1 26.0 
 
Table 9. Time-dependent relationship for miR-34a transfected BME in transwell studies (Pc 
values). 
Minutes 15.0 30.0 45.0 60.0 
Pc 
coefficient 
5.6E-06 2.8E-06 1.7E-06 2.2E-06 
3.2E-06 9.1E-07 2.3E-06 2.9E-06 
3.7E-06 6.6E-06 4.8E-06 4.6E-06 
1.9E-06 5.2E-06 3.4E-06 3.1E-06 
1.8E-05 7.9E-06 7.3E-06 4.4E-06 
1.8E-06 3.5E-06 3.6E-06 2.8E-06 
5.4E-06 3.3E-06 1.6E-06 3.7E-06 
5.6E-06 2.6E-06 1.0E-06 2.0E-06 
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5.7E-06 1.8E-06 8.5E-07 1.9E-06 
Mean 5.6E-06 3.9E-06 2.9E-06 3.1E-06 
SEM 1.6E-06 7.7E-07 6.9E-07 3.3E-07 
 
Table 10. MTT cell viability tests for bEnd.3 administered FM 4-64 labeled BME. 
Concentration 
(BME/mL) 
Control 1.5 x 1011 3 x 1011 6 x 1011 1.2 x 1012 1.8 x 1012 2.4 x 1012 
% viability 102.2 83.4 77.9 74.0 81.8 86.5 91.2 
94.4 98.3 104.6 77.9 86.5 72.4 106.9 
83.4 95.2 81.8 106.9 106.1 73.2 74.0 
95.9 115.6 142.2 103.0 123.4 88.1 81.8 
90.5 102.2 82.6 79.5 87.3 92.0 59.9 
133.6 147.7 77.1 94.4 64.6 81.8 65.4 
77.3 70.9 55.7 61.6 81.7 84.8 77.3 
88.4 59.1 84.5 102.3 101.0 108.5 102.3 
134.2 63.2 99.0 76.1 98.5 125.8 106.4 
Mean 100.0 92.8 89.5 86.2 92.3 90.4 85.0 
SEM 6.8 9.3 8.0 5.3 5.7 5.7 5.9 
 
Table 11. MTT cell viability tests for BV2 administered FM 4-64 labeled BME. 
Concentration 
(BME/mL) 
Control 1.5 x 1011 3 x 1011 6 x 1011 1.2 x 
1012 
1.8 x 
1012 
2.4 x 
1012 
% viability 104.8 117.1 91.1 93.0 107.2 105.8 67.5 
98.2 81.2 108.1 108.1 106.7 87.3 61.3 
102.9 97.7 91.1 90.1 100.1 71.7 64.6 
98.7 108.1 122.8 69.8 113.8 168.6 75.0 
94.4 92.0 113.3 84.0 95.4 81.6 82.1 
101.0 123.7 116.6 75.5 116.6 80.7 82.1 
112.4 78.8 82.1 86.5 97.4 84.8 77.4 
96.8 105.8 82.1 67.1 43.4 65.0 77.6 
90.8 121.9 109.8 124.2 103.6 69.6 71.8 
Mean 100.0 102.9 101.9 88.7 98.2 90.6 73.3 
SEM 2.1 5.6 5.1 6.1 7.2 10.5 2.5 
 
 
 
 
